Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2020 - 2023)

Cullinan Therapeutics has reported Income from Non-Controlling Interests over the past 4 years, most recently at -$1.8 million for Q4 2023.

  • Quarterly results put Income from Non-Controlling Interests at -$1.8 million for Q4 2023, down 475.16% from a year ago — trailing twelve months through Dec 2023 was -$1.9 million (down 7656.0% YoY), and the annual figure for FY2024 was -$192000.0, up 90.1%.
  • Income from Non-Controlling Interests for Q4 2023 was -$1.8 million at Cullinan Therapeutics, down from -$179000.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for CGEM hit a ceiling of $14.6 million in Q4 2020 and a floor of -$5.3 million in Q2 2020.
  • Median Income from Non-Controlling Interests over the past 4 years was -$554500.0 (2021), compared with a mean of $270571.4.
  • Biggest five-year swings in Income from Non-Controlling Interests: soared 889.47% in 2021 and later crashed 475.16% in 2023.
  • Cullinan Therapeutics' Income from Non-Controlling Interests stood at $14.6 million in 2020, then crashed by 111.59% to -$1.7 million in 2021, then skyrocketed by 81.91% to -$306000.0 in 2022, then crashed by 475.16% to -$1.8 million in 2023.
  • The last three reported values for Income from Non-Controlling Interests were -$1.8 million (Q4 2023), -$179000.0 (Q1 2023), and -$306000.0 (Q4 2022) per Business Quant data.